Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections

International Journal of Pharmaceutics

Volumn 494, Issue 1, 2015, Pages 17-22

  Moreno Rodríguez, Ana C ^a   Torrado Durán, Susana ^a,b   Molero, G ^a   García Rodríguez, Juan José ^a   Torrado Santiago, Santiago ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amphotericin B; Brain candidiasis; Efficacy; Micelle system; Sodium deoxycholate; Toxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DEOXYCHOLATE SODIUM; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; MICELLE; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN INFECTION; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; INVASIVE CANDIDIASIS; KIDNEY; LETHALITY; MALE; MICELLE; MOUSE; MYCOSIS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; CANDIDIASIS; DRUG EFFECTS; ERYTHROCYTE; MEDICINAL CHEMISTRY; MICROBIOLOGY; PROCEDURES;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BRAIN; CANDIDA ALBICANS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; DEOXYCHOLIC ACID; ERYTHROCYTES; KIDNEY; MALE; MICE; MICELLES; PARTICLE SIZE; SURFACE-ACTIVE AGENTS;

EID: 84939215029     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.08.003     Document Type: Article

References (29)

1. D. Andes, N. Safdar, K. Marchillo, and R. Conklin Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models Antimicrob. Agents Chemother. 50 2006 674 684
2. N. Arichi, H. Yasumoto, K. Ogawa, T. Nagami, H. Anjiki, S. Nakamura, Y. Mitsui, T. Hiraoka, M. Sumura, and H. Shiina Case report of a ureteral obstruction by Candida albicans fungus balls detected by magnetic resonance imaging in kidney transplant recipient Exp. Clin. Transplant. 12 2014 559 561
3. C. Cifani, S. Costantino, M. Massi, and L. Berrino Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent? Acta Biomed. 83 2012 154 163
4. K.V. Clemons, M. Espiritu, R. Parmar, and D.A. Stevens Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis Antimicrob. Agents Chemother. 49 2005 4867 4875
5. P.S. Darole, D.D. Hegde, and H.A. Nair Formulation and evaluation of microemulsion based delivery system for amphotericin B AAPS PharmSciTech 9 2008 122 128
6. R. Diez-Orejas, G. Molero, F. Navarro-García, J. Pla, C. Nombela, and M. Sanchez-Pérez Reduce virulence of Candida albicans MKC1 mutants: a role for mitogen-activated protein kinase in pathogenesis Infect. Immun. 65 1997 833 837
7. R. Espada, S. Valdespina, C. Alfonso, G. Rivas, M.P. Ballesteros, and J.J. Torrado Effect of aggregation state on the toxicity of different amphotericin B preparations Int. J. Pharm. 361 2008 64 69
8. M.S. Espuelas, P. Legrand, M.A. Campanero, M. Appel, M. Chéron, C. Gamazo, G. Barratt, and J.M. Irache Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice J. Antimicrob. Chemother. 52 2003 419 427
9. D.R. Falci, F.B. da Rosa, and A.C. Pasqualotto Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study Mycoses 58 2015 104 112
10. K.N. Gangadhar, K. Adhikari, and T. Srichana Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation Int. J. Pharm. 471 2014 430 438
11. A.H. Groll, N. Giri, V. Petraitis, R. Petraitiene, M. Candelario, J.S. Bacher, S.C. Piscitelli, and T.J. Walsh Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system J. Infect. Dis. 182 2000 274 282
12. I.D. Jacobsen, A. Lüttich, O. Kurzai, B. Hube, and M. Brock In vivo imaging of disseminated murine Candida albicans infection reveals unexpected host sites of fungal persistence during antifungal therapy J. Antimicrob. Chemother. 69 2014 2785 2796
13. C. Kang, M.S. Rouse, J.N. Mandrekar, J.M. Steckelberg, and R. Patel Anidulafungin treatment of candidal central nervous system infection in a murine model Antimicrob. Agents Chemother. 53 2009 3576 3578
14. M. Larabi, A. Gulik, J. Dedieu, P. Legrand, G. Barratt, and M. Cheron New lipid formulation of amphotericin B: spectral and microscopic analysis Biochim. Biophys. Acta 1664 2004 172 181
15. N. Lincopan, P. Borelli, R. Fock, E.M. Mamizuka, and A.M. Carmona-Ribeiro Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio Exp. Toxicol. Pathol. 58 2006 175 183
16. N. Lincopan, E.M. Mamizuka, and A.M. Carmona-Ribeiro In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments J. Antimicrob. Chemother. 52 2003 412 418
17. M. Ruhnke, G. Kofla, K. Otto, and S. Schwartz CNS aspergillosis: recognition, diagnosis and management CNS Drugs 21 2007 659 676
18. J. Sánchez-Portocarrero, E. Pérez-Cecilia, O. Corral, J. Romero-Vivas, and J.J. Picazo The central nervous system and infection by Candida species Diagn. Microbiol. Infect. Dis. 37 2000 169 179
19. M. Sandoval-Denis, F.J. Pastor, J. Capilla, D.A. Sutton, A.W. Fothergill, and J. Guarro In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae Int. J. Antimicrob. Agents 43 2014 161 164
20. S. Selvam, M.E. Andrews, and A.K. Mishra A photophysical study on the role of bile salt hydrophobicity in solubilizing amphotericin B aggregates J. Pharm. Sci. 98 2009 4153 4160
21. C. Serena, F.J. Pastor, M. Marine, M.M. Rodriguez, and J. Guarro Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection J. Antimicrob. Chemother. 60 2007 162 165
22. D.R. Serrano, L. Hernández, L. Fleire, I. González-Alvarez, A. Montoya, M.P. Ballesteros, M.A. Dea-Ayuela, G. Miró, F. Bolás-Fernández, and J.J. Torrado Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations Int. J. Pharm. 447 2013 38 46
23. K. Shao, R. Huang, J. Li, L. Han, L. Ye, J. Lou, and C. Jiang Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain J. Control. Release 147 2010 118 126
24. M.A. Silva-Filho, S.D.V. Siqueira, L.B. Freire, I.B. Araújo, K.G.H. Silva, A.C. Medeiros, I. Araújo-Filho, A.G. Oliveira, and E.S.T. Egito How can micelle systems be rebuilt by a heating process? Int. J. Nanomed. 2012 7141 7150
25. V. Strenger, A. Meinitzer, J. Donnerer, N. Hofer, H.J. Dornbusch, U. Wanz, M.G. Seidel, D. Sperl, H. Lackner, W. Schwinger, P. Sovinz, M. Benesch, and C. Urban Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B J. Antimicrob. Chemother. 69 2014 2522 2526
26. W. Tiyaboonchai, and N. Limpeanchob Formulation and characterization of amphotericin B-chitosan-dextran sulfate nanoparticles Int. J. Pharm. 329 2007 142 149
27. J.J. Torrado, R. Espada, M.P. Ballesteros, and S. Torrado-Santiago Amphotericin B formulations and drug targeting J. Pharm. Sci. 97 2008 2405 2425
28. E.W.M. van Etten, W. van Vianen, P. Roovers, and P. Frederik Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice Antimicrob. Agents Chemother. 44 2000 1598 1603
29. Y. Zu, W. Sun, X. Zhao, W. Wang, Y. Li, Y. Ge, Y. Liu, and K. Wang Preparation and characterization of amorphous amphotericin B nanoparticles for oral administration through liquid antisolvent precipitation Eur. J. Pharm. Sci. 53 2014 109 117